229 related articles for article (PubMed ID: 37740888)
1. Obesity: a gender-view.
Muscogiuri G; Verde L; Vetrani C; Barrea L; Savastano S; Colao A
J Endocrinol Invest; 2024 Feb; 47(2):299-306. PubMed ID: 37740888
[TBL] [Abstract][Full Text] [Related]
2. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
[TBL] [Abstract][Full Text] [Related]
3. Gender-related issues in the pharmacology of new anti-obesity drugs.
Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
[TBL] [Abstract][Full Text] [Related]
4. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
[TBL] [Abstract][Full Text] [Related]
6. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
[TBL] [Abstract][Full Text] [Related]
7. Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.
Suliman M; Buckley A; Al Tikriti A; Tan T; le Roux CW; Lessan N; Barakat M
Diabetes Obes Metab; 2019 Jun; 21(6):1498-1501. PubMed ID: 30768836
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
9. Antiobesity drugs before and after bariatric surgery - how to make the best use of them.
Šrámková P; Fried M
Cas Lek Cesk; 2022; 161(3-4):107-113. PubMed ID: 36100447
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide: A New Option for the Treatment of Obesity.
Nuffer WA; Trujillo JM
Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
[TBL] [Abstract][Full Text] [Related]
12. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Nuffer W; Trujillo JM; Megyeri J
Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
[TBL] [Abstract][Full Text] [Related]
14. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
Khalil H; Ellwood L; Lord H; Fernandez R
Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
[No Abstract] [Full Text] [Related]
16. New treatment modalities for obesity.
Grandone A; Di Sessa A; Umano GR; Toraldo R; Miraglia Del Giudice E
Best Pract Res Clin Endocrinol Metab; 2018 Aug; 32(4):535-549. PubMed ID: 30086873
[TBL] [Abstract][Full Text] [Related]
17. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
19. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
20. Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
Wilding JPH
Clin Obes; 2018 Jun; 8(3):211-225. PubMed ID: 29689646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
